

Table 1. Demographic/clinical and histological features of oxyntic gland mucosa cases according to GR distribution pattern

	GR distribution pattern (0, 1) (n=20)	GR distribution pattern (2, 3) (n=14)	P-value
Clinical features			
Age, years, range (median)	47-86 (68)	39-83 (72)	0.56
Sex, no. (%)			
Male	14 (70)	9 (64.3)	1
Female	6 (30)	5 (35.7)	
Medication, no. (%)			
PPI	5 (25)	10 (71.4)	0.034*
H2-receptor antagonists	2 (10)	0 (0)	0.51
Location in the stomach, no. (%)			
U	15 (75)	7 (50)	0.16
M	5 (20)	7 (50)	
L	0 (0)	0 (0)	
Histological features			
Foveolar cell hyperplasia-like change, no. (%)	4 (20)	5 (35.7)	0.7
Parietal cell change, no. (%)	4 (20)	6 (42.9)	0.13
Mononuclear inflammatory cell infiltration, no. (%)	0 (0)	1 (7.1)	0.38

GR: gastrin receptor PPI: proton pump inhibitor no.: number of cases * $P < 0.05$

Table 2. Measurement of indicators for the evaluation of organization of oxyntic gland mucosa according to GR distribution pattern or history of PPI medication

Indicators, range (median)	GR distribution pattern (0, 1) (n=20)	GR distribution pattern (2, 3) (n=14)	P-value	PPI (-) (n=19)	PPI (+) (n=15)	P-value
(a) Thickness of the mucosa, μm (a)	522.0-1454 (830.7)	400.5-1448 (890.2)	0.726	400.5-1171 (751.56)	514.0-1454 (932.14)	< 0.01*
(b) Thickness of the oxyntic gland, μm	413.0-1221 (694.8)	295.7-1213 (686.0)	0.861	295.74-922 (601.93)	375.0-1221 (774.0)	< 0.01*
(c) Ratio of thickness of MUC5AC+ foveolar epithelium to total mucosa, %	11.27-28.21 (20.04)	13.87-30.35 (20.28)	0.6	12.35-28.21 (20.14)	11.27-30.35 (20.24)	0.755
(d) Ratio of thickness of MUC5AC+ dispersed cells in neck region to total mucosa, %	3.844-53.15 (9.871)	10.09-56.26 (21.20)	< 0.01*	3.844-24.56 (9.972)	5.863-56.26 (20.20)	< 0.01*
(e) Ratio of total thickness of MUC5AC+ layer to total mucosa, =(c)+(d), %	16.19-65.24 (33.70)	23.96-76.60 (42.38)	< 0.01*	16.19-47.01 (32.68)	17.13-76.60 (40.44)	< 0.01*
(f) Ratio of thickness of MUC6+ layer to total mucosa, %	15.76-68.49 (40.44)	28.22-82.82 (60.73)	0.0229*	15.76-68.49 (38.09)	38.88-82.82 (60.81)	< 0.01*
(g) Ratio of thickness of Ki67+ layer to total mucosa, %	2.813-14.05 (8.905)	4.120-18.86 (10.21)	0.115	2.813-14.05 (10.30)	4.878-18.86 (8.779)	0.862
(h) Ki67 positive rate in the oxyntic gland area, %	0.22-1.55 (0.650)	0.43-2.70 (0.725)	0.141	0.22-1.36 (0.66)	0.31-2.70 (0.67)	0.716

For the definition and measurement of each variable (a to h) in the left column, see Fig. 3

GR: gastrin receptor PPI: proton pump inhibitor * $P < 0.05$

Table 3. Demographic/clinical and histological features of fundic gland polyp cases according to history of PPI medication.

	PPI (+) (n=25 ^{\$})	PPI (-) (n=8 ^{\$})	P-value
Clinical features			
Age, years, range (median)	23-87 (71)	30-80 (48)	0.0883
Sex, no. (%)			
Male	12 (48)	3 (37.5)	0.70
Female	13 (52)	5 (62.5)	
	PPI (n=33 [#])	Non-PPI (n=10 [#])	P-value
Clinical features			
Medication, no. (%)			
H2-receptor antagonists	0 (0)	0 (0)	1
Location in the stomach, no. (%)			
U	12 (36)	7 (70)	0.079
M	21 (64)	3 (30)	
L	0 (0)	0 (0)	
Mean diameter of polyps, mm, range (median)	3-25 (10)	4-10 (5)	< 0.01 [*]
Histological features			
Max diameter of cystic fundic gland, μ m, range (median)	107-1168 (242)	65-643 (239)	0.585
Foveolar cell hyperplasia-like change, no. (%)	33 (100)	7 (70)	< 0.01 [*]
Parietal cell change, no. (%)	27 (81.8)	0 (0)	< 0.01 [*]
Mononuclear inflammatory cell infiltration no. (%)	3 (30)	3 (9.1)	0.127
Ki-67 labelling index in the following part			
Superficial layer, %, range (median)	1.20-17.61 (5.52)	2.38-9.09 (4.64)	0.49
Deeper layer, %, range (median)	0.99-12.18 (3.920)	0.95-8.53 (3.935)	0.863

^{\$} number of patients [#] number of cases no.: number of cases or samples * $P < 0.05$